For sales

📢Highlights from the Week of 30 June, 2025 – 07 July, 2025 in the world of pharma and healthcare! 🗞️👀

Highlights from the Week of 30 June, 2025 - 07 July, 2025 Unicycive Therapeutics receives a complete response letter for oxylanthanum carbonate to treat hyperphosphatemia in dialysis patients with chronic kidney disease Takeda receives US FDA approval for GAMMAGARD LIQUID ERC, a ready-to-use low IgA therapy for primary immunodeficiency; the launch is planned for 2026, with the first-generation product to be discontinued Positive results from Amgen’s Phase 3 trial showed that bemarituzumab plus chemotherapy significantly improves overall survival over chemotherapy alone in FGFR2b-positive gastric cancer (Clinical trial, Results) (FDA Approval) (FDA, CR) Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.